# Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy

Study · id `cardio:ct-nct01434134` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01434134](<https://clinicaltrials.gov/study/NCT01434134>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01434134

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT01434134. Randomized; quadruple masking; primary purpose prevention. Start 2011-09 (registry gives no type); primary completion 2014-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT01434134, source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01434134, source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01434134, source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)
- Completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01434134, source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT01434134, source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01434134-2014-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy
- Acronym: PRADA
- Condition: Breast Cancer
- Condition: Heart Failure
- Intervention (Drug): Metoprolol
- Intervention (Drug): Placebo
- Intervention (Drug): Candesartan
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Akershus
- Lead sponsor class: OTHER
- Collaborator: University of Oslo
- Collaborator class: OTHER
- Collaborator: Norwegian Cancer Society
- Collaborator class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Metoprolol (`cardio:metoprolol`)
- Registry intervention name matches this record: Candesartan (`cardio:candesartan`)
- Registry lists this organization as the lead sponsor: University Hospital, Akershus (`cardio:org-university-hospital-akershus`)
- Registry lists this organization as a collaborator: University of Oslo (`cardio:org-university-of-oslo`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study (`cardio:pubmed-29118031`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol (`cardio:pubmed-33993702`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1f2a879ef76f0c48c416a05bebd304e1996566555bb4291d1b035a04b484f917
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
